Onyda XR (clonidine suspension) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:			
that is important for the re		lab data, to support th	 Attach any additional documentatione authorization request). Information 		
			☐ URGE	NT	
MEMBER INFORMATION	ON				
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:		1			
CITY:		STATE:	ZIP CODE:		
PATIENT INSURANCE	ID NUMBER:				
MALE FEMALE	HEIGHT (IN/CM):	WEIGHT (LB/KG):	ALLERGIES:		
DISCLOSURE AUTHOR FOLLOWING LINK: PRI	PATIENT OR THE PRESC IZATION FORM WITH TH METHERAPEUTICS.COM ED REPRESENTATIVE (II	IIS REQUEST WHICI M/NOPP	I CAN BE FOUND AT THE		
	ENTATIVE'S PHONE NU				
PRESCRIBER INFORM	IATION				
LAST NAME:	ATION	FIRST NAME:			
PRESCRIBER SPECIA	I TV·	EMAII ADDRE	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:					
CITY:		STATE:	ZIP CODE:		
REQUESTER (if different than prescriber):		OFFICE CONT	OFFICE CONTACT PERSON:		
	ICAL DISPENSING INFO	RMATION			
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:		
☐ NEW THERAPY	RENEWAL IF		HERAPY INITIATED:		
DURATION OF THERA	PY (SPECIFIC DATES):				
Continued on next page					

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 5.1.25 CAT009



Onyda XR (clonidine suspension) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:					
	OTHER MEDICATIONS FOR THIS NO	CONDITION?			
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
Attention Deficit/Hyperactivity Di Other diagnosis:	sorder(ADHD) ICD-10 Code(s):				
TO SUPPORT A PRIOR AUTHORI					
Is patient going to be using drug	in combination with a clinical trial	? ∐ Yes ∐ No			
Initial Request: Does patient have rationale why to the Please provide chart documentate	they require the extended- release ion.	formulation?			
Does patient have difficulty swall	owing a tablet? Yes No Ple	ase provide chart documentation.			
Has patient tried the tablet formulation by crushing and using the tablet formulation as a suspension or crushed and used in a small amount of loose food like apple sauce, pudding, or the like? No Please provide chart documentation.					
If yes to the above,did patient has swallowing? Yes No Pleas	ve a lack of efficacy when crushing se provide chart documentation.	g the tablet formulation and			
Renewal Request: Does patient continue to require documentation.	the liquid formulation? Yes	No Please provide chart			
Does patient have additional table Please provide chart documentate	ets and or capsules that they crustion.	h and swallow? Yes No			
Are there any other comments, d information the physician feels is	iagnoses, symptoms, medications important to this review?	tried or failed, and/or any other			
Please note: Not all drugs/diagnosi required information is received.	s are covered on all plans. This requ	est may be denied unless all			

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 5.1.25 CAT009



Onyda XR (clonidine suspension) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:	
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.	
Prescriber Signature or Electronic I.D. Verification: Date:	_
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.	
FAX THIS FORM TO: 800-424-7640	

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

